Ribavirin in cancer immunotherapies: Controlling nitric oxide augments cytotoxic lymphocyte function

Neoplasia

Volumn 5, Issue 1, 2003, Pages 3-8

  Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Adjuvant; Cancer immunotherapy; Hepatitis C; Inflammation; Interferon alpha; Lymphocyte; Macrophage; Nitric oxide

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; IMMUNOLOGICAL ADJUVANT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHORYL LIPID A; RIBAVIRIN; TETRAHYDROBIOPTERIN; THERATOPE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BREAST CANCER; CANCER IMMUNOTHERAPY; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; ANTIMETABOLITES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RIBAVIRIN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS;

EID: 0037247674     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Fairbanks LD, Bofill M, Ruckemann K, and Simmonds HA (1995), Importance of ribonucleotide to proliferating T lymphocytes from healthy humans, J Biol Chem 270, 29682-89.
2. Brodsky RA (2002). High dose cyclophosphamide foraplastic anemia and autoimmunity. Curr Opin Oncol 14, 143-46.
3. Jankovic D, Liu Z, and Gause WC (2001). Th1 and Th2 cell commitment during infectious disease. Trends Immunol 22, 450-73.
4. Martin S, Hibino T, Faust A, Kleemann R, and Kolb H (1996). Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in insulitis of NOD mice and association with both Th-1 and Th2 infiltrates. J Autoimmun 9, 637-43.
5. Rothe H, Faust A, Schade U, Kleemann R, Bosse G, Hibino T, Martin S, and Kolb H (1994). Cyclophosphamide treatment of female NOD mice causes enhanced iNOS and IFN-gamma, but not of II-4. Diabetologia 37, 1154-58.
6. Faulkner-Jones BE, Dempsey-Collier M, Mandel TE, and Harrison LC (1996). Both Th1 and Th2 cytokine mRNA are expressed in NOD mouse pancreas in vivo. Autoimmunity 23, 99-110.
7. Nitta Y, Kawamoto S, Tashiro F, et al (2001). II-12 plays a pathologic role at the inflammatory loci in the development of diabetes in NOD mice. J Autoimmunity 16, 97-104.
8. Reddy S, Karanam M, Poole CA, and Ross JM (2000). Dual label immunohistochemical study of II-4 and IFN-gamma cells within pancreas of NOD mouse during disease acceleration with cyclophosphamide. Autoimmunity 32, 181-92.
9. Martin S, van den Engel NK, and Vinke A, et al (2001). Dominant role of ICAM-1 in the pathogenesis of autoimmune diabetes in NOD mice. J Autoimmunity 17, 109-17.
10. Rothe H, Burkart V, Faust A, and Kolb H (1996). II-12 gene expression mediates the accelerating effect of cyclophosphamide in autoimmune disease. Ann N Y Acad Sci 795, 397-99.
11. Trembleau S, Penna G, Gregori S, Gately MK, and Adorini L (1997). Deviation of pancreas infiltrating cells to Th2 by II-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 27, 2330-39.
12. Ben-Efraim S (2001). Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets 2, 197-212.
13. Ablamunits V, Quintana F, Reshef T, Elias D, and Cohen IR (1999). Acceleration of diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway. J Autoimmun 13, 383-92.
14. Matar P, Rozados VR, Gervasoni SLLI, and Scharovsky GO (2002). Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50, 588-96.
15. Cao X, Zhang W, Wan T, Yu Y, Tao Q, and Wang J (1999). Enhanced antitumor immune responses of II-2 gene modified tumor vaccine by combination with II-1 and low dose cyclophosphamide. J Exp Clin Cancer Res 18, 173-79.
16. Li L, Okino T, and Kan N, et al (1998). Analysis of effector cells in tumor bearing mice pre-treated with active specific immunization followed by cyclophosphamide. Biotherapy 11, 223-28.
17. Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, and Soma G (1998). Mechanisms by which chemotherapeutic agents augment the antitumor effects of TNF-alpha: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 18(5D), 3957-64.
18. Livingston PO, DeLeo AB, Jones M, and Oettgen HF (1983). Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene induced sarcoma MethA: pretreatment with cyclophosphamide is most effective. J Immunol 131, 2601-605.
19. Tsung K, Meko JB, Tsung YL, Peplinski GR, and Norton JA (1998). Immune response against large tumors eradicated by treatment with cyclophosphamide and II-12. J Immunol 1160, 1369-77.
20. MacLean GD, Reddish MA, Koganty RR, and Longenecker BM (1996). Antibodies against mucin associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19, 59-68.
21. MacLean GD, Miles DW, Rubens RD, Reddish MA, and Longenecker BM (1996). Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low dose i.v. cyclophosphamide. J Immunother Emphasis Tumor Immunol 19, 309-16.
22. Karanikas V, Thynne G, and Mitchell P, et al (2001). Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of administration. J Immunol 24, 172-83.
23. Euhus DM, Gupta RK, and Morton DL (1989). Induction of antibodies to a tumor associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol 29, 247-54.
24. Smith DR, Balashov KE, Hafler DA, Khoury SJ, and Weiner HL (1997). Immune deviation following pulse cyclophosphamide methylprednisolone treatment of MS, increased II-4 and associated eosinophilia. Ann Neurol 42, 313-18.
25. Boyer N, and Marcellin P (2000). Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 32(1 Suppl), 98-112.
26. Kast RE (2002). Chronic mild encephalopathy of hepatitis C virus: evidence for a common psychiatric illness. Psychiatry Online (in press).
27. Hultgren C, Millich DR, Weiland O, and Sallberg M (1998). The antiviral compound ribavirin modulates T1/Th2 subset balance in hepatitis B and C virus specific immune responses. J Gen Virol 79(Pt 10), 2381-91.
28. Querenghi F, Yu Q, Billaud G, Maetens G, Trepo C, and Zoulim F (2001). Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepatol 8, 120-31.
29. Reichard O, Sonnerborg A, and Weiland O (1993). HCV RNA titers prior to, during, and after oral RBV treatment. J Med Med Virol 41, 99-102.
30. Di Bisceglie AM, Hoofnagle JH, and Krawczynski K (1993), Changes in HCV antigen in liver with antiviral therapy. Gastroenterology 105, 858-62.
31. Reichard O, Andersson J, Schvarcz R, and Weiland O (1991). RBV treatment for chronic HCV. Lancet 337, 1058-61.
32. McHutchison JG, Shad JA, and Gordon SC, et al (2001). Predicting response to initial therapy with IFN plus ribavirin in chronic HCV using serum HCV RNA results during therapy. J Viral Hepat 8, 414-20.
33. Powers CN, Peavy DL, and Knight V (1982). Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother 22, 108-14.
34. Tam RC, Ramasamy K, Bard J, Pal B, Lim C, and Averett DR (2000). Ribavirin analogue ICN 17261 demonstrates reduced toxicity with retention of both immunomodulatory activity and reduction of hepatitis induced serum alanine transferase levels. Antimicrob Agents Chemother 44, 1276-83.
35. Ramasamy KS, Tam RC, Bard J, and Averett DR (2000). Monocyclic L nucleosides with type 1 cytokine inducing activity. J Med Chem 43, 1019-28.
36. Fairbanks LD, Bofill M, Ruckemann K, and Simmonds HA (1995). Importance of ribonucleotide availability to proliferating T lymphocytes from healthy humans. J Biol Chem 270, 29682-89.
37. Mills CD (2001). Macrophage arginine metabolism to orinthine/urea or NO/citrulline: a life or death issue. Crit Rev Immunol 21, 399-426.
38. Hurshman AR, and Marletta MA (2002). Reactions catalysed by the heme domain of iNOS synthase: evidence for the involvement of BH4 in electron transfer. Biochemistry 41, 3439-56.
39. Hokari A, Zeniya M, and Esumi H, et al (2002). Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J Gastroenterol Hepatol 17, 308-15.
40. Schweyer S, Mihm S, Radzun HJ, Hartmann H, and Fayyazi A (2000). Liver infiltrating T lymphocytes express IFN-gamma and iNOS in HCV infection. Gut 46, 255-59.
41. Mihm S, Fayyazi A, and Ramadori G (1997). Hepatic expression of iNOS transcripts in chronic HCV infection: relation to hepatic viral load and liver injury. Hepatology 26, 451-58.
42. Kane JM III, Shears LL II, Hierholzer C, Ambs S, Billiar TR, and Posner MC (1997). Chronic HCV infection: induction of hepatic NOS and proposed mechanisms for carcinogenesis. J Surg Res 69, 321-24.
43. Lake-Bakaar G, Sorbi D, and Mazzoccoli V (2001). NO and chronic HCV and HIV infections. Dig Dis Sci 46, 1072-76.
44. Sharara AI, Perkins DJ, and Misukonis MA, et al (1997). IFN-alpha activation of human blood mononuclear cells in vitro and in vivo for NOS type 2 mRNA and protein expression: possible relationship of induced NOS 2 to the anti-HCV effects of IFN-alpha in vivo. J Exp Med 186, 1495-502.
45. Brassard DL, Grace MJ, and Bordens RW (2002). IFN-alpha as an immunotherapeutic protein. J Leukoc Biol 71, 565-81.
46. Caradonna L, Mastronardi ML, and Magrone T, et al (2002). Biological and clinical significance of endotoxinemia in the course of HCV infection. Curr Pharm Des 8, 995-1005.
47. Saio M, Radoja S, Marino M, and Frey AB (2001). Tumor infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell associated form of TNF and nitric oxide. J Immunol 167, 5583-93.
48. Nascimento FR, Calich VL, Rodriguez D, and Russo M (2002). Dual role for NO in paracoccidioidomycosis: essential for resistance, but overproduction associated with susceptibility. J Immunol 168, 4593-600.
49. Li WJ, and Gottstain B (1999). NO mediated immunosuppression following murine Echinococcus multilocularis infection. Immunology 97, 107-16.
50. Wright KL, and Ward SG (2000). Interactions between phosphatidyl-inositol 3 kinase and NO: explaining the paradox. Mol Cell Biol Res Commun 4, 137-43.
51. Juedes AE, and Ruddle NH (2001). Resident and infiltrating CNS APC's regulate the emergence and resolution of EAE. J Immunol 166, 5168-75.
52. Roozendaal R, Vellenga E, and de Jong MA, et al (2001). Resistance of activated Th2 cells to NO induced apoptosis is mediated by gamma glutamyltranspeptidase. Int Immunol 13, 519-28.
53. van der Veen RC, Dietlin TA, Pen L, Gray JD, and Hofman FM (2000). Antigen presentation to Th1 but not Th2 cells by macrophages results in NO production and inhibition of T cell proliferation: IFN-gamma is essential but insufficient Cell Immunol 206, 125-35.
54. Mendes RV, Martins AR, de Nucci G, Murad F, and Soares FA (2001). Expression of NOS isoforms and nitrotyrosine immunoreactivity by B cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology 39, 172-78.